Faculty Collaboration Database

A Behavioral Intervention to Improve Symptoms After Hematopoietic Cell Transplantation. J Pain Symptom Manage 2026 Aug;72(2):131-142

Date

04/19/2026

Pubmed ID

42000061

Pubmed Central ID

PMC13215335

DOI

10.1016/j.jpainsymman.2026.04.006

Scopus ID

2-s2.0-105038855692 (requires institutional sign-in at Scopus site)

Abstract

CONTEXT: Fatigue, insomnia, and depression are persistent, burdensome symptoms for patients recovering from hematopoietic cell transplantation (HCT). Restoring Sleep and Energy after Transplant (ReSET) is a novel behavioral intervention designed to alleviate these symptoms by optimizing patients' 24-hour rest-activity patterns.

OBJECTIVES: The primary aim was to evaluate the feasibility and acceptability of ReSET. An exploratory aim was to determine preliminary effect sizes.

METHODS: This pilot randomized controlled trial compared ReSET to usual care. Participants randomized to ReSET completed three in-person intervention sessions at approximately 3-4, 8, and 12 weeks post-HCT that focused on strategies to improve nighttime sleep and increase nonsedentary daytime activity. All participants wore an actigraphy device (Philips) and completed patient-reported outcome measures (PROMIS sleep disturbance, fatigue, and depression) pre-HCT (T0), 9 (T1), and 18 weeks post-HCT (T2). Interviews were conducted at T2. Ability to recruit, retain, and collect complete data from participants and participant engagement with the intervention were the primary measures of feasibility and acceptability. Interviews were conducted at T2 to provide supplementary insight regarding participant satisfaction and barriers to completion.

RESULTS: Thirty-nine patients were randomized, and most (n = 35; 89.7%) completed the study. Most ReSET participants (85%) completed all intervention sessions. PROMs of sleep (η² = 0.033) and depression (η² = 0.015) improved over time for participants in ReSET compared to usual care. Those randomized to ReSET also showed improved rest-activity rhythms relative to usual care, including mesor (η² = 0.044), amplitude (η² = 0.087), and R-squared (η² = 0.073) actigraphy indices.

CONCLUSION: ReSET demonstrated feasibility, acceptability, and preliminary promise for intervention efficacy.

Author List

Hoeve ESV, Alzoubi B, Rumble ME, Cadmus-Bertram L, Juckett MB, Callander NS, Hematti P, Costanzo ES

Author

Peiman Hematti MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Actigraphy
Adult
Aged
Behavior Therapy
Depression
Fatigue
Feasibility Studies
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Middle Aged
Patient Reported Outcome Measures
Pilot Projects
Sleep Wake Disorders
Treatment Outcome